The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the Blueprint Neurotherapeutics Network (BPN) funding opportunity aimed at advancing small molecule drug discovery and development for nervous system disorders. This program encourages applications from neuroscience researchers to conduct exploratory and developmental phases of drug development, retaining intellectual property rights while collaborating with NIH consultants and contract organizations. The opportunity focuses on optimizing and testing compounds through rigorous study milestones and phases, specifically targeting conditions aligned with participating NIH institutes such as NINDS, NIA, and NIMH. Key dates encompass application openings in December 2024, with specific submission requirements and project duration not exceeding five years. The program emphasizes adherence to regulatory standards, diversity in research teams, and obtaining prior approval for clinical trials, ultimately seeking to facilitate efficient pathways for novel therapeutic solutions while mitigating risks associated with drug development. Interested applicants must prepare thorough applications, demonstrating innovative approaches and clear alignment with NIH's objectives in neuroscience research.